uniQure N.V. (QURE) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, QURE scores 37 out of 100 with a letter grade of D- and the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC of -35% and FCF yield of -10.17%), Whale 13F Flow at 4/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 9/20 (Beta 1.0 with sector sensitivity), and Forensic Balance Sheet at 13/20 (Altman Z 2.5, Piotroski F 4/9, Debt/Equity 0.25). The weakest pillars are Whale 13F Flow and Insider Conviction, while Forensic Balance Sheet is the strongest relative to its weight. For a prospective investor, the rating points to negative cash generation as the central issue: the rating's own inputs show negative ROIC and negative free cash flow yield, meaning the business is consuming rather than producing cash on the figures provided. The balance-sheet pillar is the main counterweight, with a Debt/Equity of 0.25 and a Piotroski score of 4/9, but these do not offset the cash-flow weakness within the rating's framework. Upside drivers would need to come from catalysts that change the cash trajectory, which the source data does not establish. Valuation cannot be assessed from earnings multiples because P/E and EV/EBITDA are not available in source data. This analysis is educational and is not personalized financial advice.

Per the profile section, uniQure N.V. (QURE) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The source data does not describe its products, customers, or revenue model. Revenue is reported as $0.0M across the available periods. Not available in source data for further business detail.

Per the SEC financials, revenue is $0.0M in each reported period and operating and net losses persist across FY 2023 through FY 2025. Gross, operating, and net margins are each reported as 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 4/9. Cash declined from $158.9M in FY 2024 to $80.2M in FY 2025, while debt was $49.7M in FY 2025 against $51.3M in FY 2024.

The news feed contains six headlines, all relating to QURE. A Seeking Alpha item is titled "uniQure: The Market Graded The Wrong Exam," and a Yahoo Finance item reports a 5.9% decline following a Huntington's gene therapy data update. A marketscreener.com item reports shares falling after a Barclays downgrade, which is the only item flagged RISK WATCH (RED) in the feed. The remaining items are general market-wire coverage flagged YELLOW, including Yahoo! Finance Canada, TradingView, and Simply Wall St pages. The Butterfly Supply-Chain Graph lists no supply-chain relationships and no proprietary signals, so it adds no dependency-based catalysts. The article bodies are not included in the source data, so the specific content of the data update and the downgrade rationale is not available in source data.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations beyond the stated Health Care classification, and second-order bottlenecks are not available in source data.

• What were the specific results of the Huntington's gene therapy data update, and how did they bear on the reported 5.9% decline?
• What was the rationale behind the Barclays downgrade flagged in the news feed?
• Does the company generate or expect any revenue, given that revenue is reported as $0.0M across all periods?
• What is the cash runway implied by the FY 2025 cash balance of $80.2M against the FY 2025 free cash flow of $-178.4M?
• What are the company's equity valuation inputs, given that P/E, EV/EBITDA, and EPS are not available in source data?